The major focus of the Rae Lab has been the study of the preclinical and clinical translation aspects of breast cancer. Our work includes original studies in cancer drug metabolism, pharmacogenetics/genomics, translational oncology, biomarker identification and characterization; particularly as these may apply to the prediction of breast cancer treatment response. 

Pharmacogenetics is the study of how a patient’s unique genetic makeup influences therapeutic response and adverse reactions to drugs.  We have been developing the means to identify patients who are likely to respond to specific breast cancer drugs by studying how inherited genetic variants affect the way patients activate and eliminate certain drugs including the anti-estrogens tamoxifen and aromatase inhibitors.

From left to right: Christina Gersch, Dr. José Larios, Dr. James Rae, Chris Paclibar, Jacklyn Thibert, Cameron Capper, Lauren McIntosh